IP Library Granted Patent US 9,234,170
Granted Patent B2
US 9,234,170 · App. 13/643,032 · Granted Jan 12, 2016

Generation of anterior foregut endoderm from pluripotent cells

Inventors: Hans-Willem Snoeck (Brooklyn, NY); Michael Green (New York, NY)
Assignee: MOUNT SINAI SCHOOL OF MEDICINE
C12N5/0607C12N5/0617C12N5/0688C12N2501/117C12N2501/119C12N2501/15C12N2501/155C12N2501/385C12N2501/41C12N2501/415C12N2506/02C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,234,170
App. No.
13/643,032
Granted
Jan 12, 2016
Kind
B2
Abstract

The invention is directed to in vitro methods of inducing differentiation of anterior foregut endoderm and the enriched populations of anterior foregut endoderm produced by such methods. Such enriched populations are useful for studies of the molecular events that occur during differentiation and for generating cells for cell replacement therapy.

Claims (12)

1. A method of deriving an anterior foregut endoderm cell, the method comprising culturing a definitive endoderm cell derived from a pluripotent cell, in the presence of an inhibitor of bone morphogenetic protein (BMP) and in the presence of an inhibitor of transforming growth factor beta (TGF-beta) signaling.

2. The method of claim 1 , wherein the definitive endoderm cell is cultured in the absence of Activin A.

3. The method of claim 1 , wherein the inhibitor of BMP is Noggin, Chordin, or follistatin.

4. The method of claim 3 , wherein the inhibitor of BMP is Noggin.

5. The method of claim 1 , wherein the inhibitor of TGF-beta signaling is SB-431542.

6. The method of claim 2 , wherein the BMP inhibitor is Noggin and the inhibitor of TGF-beta signaling is SB-431542.

7. The method of claim 1 , wherein the definitive endoderm cell is an embryoid body cell.

8. The method of claim 1 , wherein the anterior foregut endoderm cell is a human cell.

9. The method of claim 1 , wherein the pluripotent cell is an embryonic stem cell.

10. The method of claim 1 , wherein the pluripotent cell is an induced pluripotent stem cell.

11. The method of claim 1 , wherein the pluripotent cell is a human cell.

12. The method of claim 1 , wherein the anterior foregut endoderm cell expresses Foxa2 and comprises an elevated level of Sox2 expression and a reduced level of Cdx2 expression, compared to the expression of Sox2 and Cdx2 in the definitive endoderm cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 14, 2016
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040026/0057 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2013
From: SNOECK, HANS-WILLEM; GREEN, MICHAEL
To: MOUNT SINAI SCHOOL OF MEDICINE
Reel/Frame 029620/0344 →
Continuity (4)
Provisional Application 61436166 · Jan 25, 2011
Provisional Application 61392429 · Oct 12, 2010
Provisional Application 61343272 · Apr 25, 2010
Related Publication 20130217005A1 · Aug 22, 2013